financetom
Business
financetom
/
Business
/
Levi's bleak 2025 profit forecast after strong holiday quarter hits shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Levi's bleak 2025 profit forecast after strong holiday quarter hits shares
Jan 29, 2025 4:30 PM

(Reuters) - Levi Strauss forecast annual profit well below analysts' estimates, taking a cautious stance despite a strong holiday quarter and sending its shares down about 8% in extended trading on Wednesday.

The company's struggling U.S. wholesale business returned to revenue growth after six quarters of decline, as newness in its collections, including men's apparel, attracted demand from retailers.

Still, executives on a post-earnings call said they expect the channel to be flat in 2025.

"We recognize there continues to be a lot of uncertainty related to the macro environment, potential changes in tariffs, as well as worsening foreign exchange... the best approach for us is to plan prudently," finance head Harmit Singh said.

The company projected annual adjusted profit per share of $1.20 to $1.25, compared with expectations of $1.37, according to data compiled by LSEG.

The forecast "underscores the uncertainty facing many retailers as they struggle to navigate President Trump's tariff threats and a more unpredictable environment - although Levi's limited exposure to China, Mexico, and Canada means it is better equipped than most to navigate those headwinds," said Rachel Wolff, analyst at EMarketer.

Levi introduced an organic revenue growth target of 3.5% to 4.5% for fiscal 2025, excluding the impact of divested business and foreign exchange rates.

It expects reported net revenue to fall between 1% and 2%. Analysts had estimated 2025 revenue to rise 3.7%.

In the holiday quarter, customers bought Levi's trendy denim dress collection and wide-legged bottoms, lifting net revenue 8% to $1.84 billion and beating estimates of $1.73 billion.

Under Michelle Gass, who completed one year at the top in January, Levi has trimmed its portfolio and focused on its direct-to-consumer channel.

Excluding items, the company earned 50 cents per share in the reported quarter, topping estimates by 2 cents.

(Reporting by Juveria Tabassum in Bengaluru; Editing by Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pasinex Flags
Pasinex Flags "Slight Delay" in Filing Q1 Financial Statements
May 24, 2024
08:31 AM EDT, 05/24/2024 (MT Newswires) -- Pasinex Resources ( PSXRF ) said Friday that it expects a slight delay in filing its interim financial statements for the first quarter that are due by May 30. The company, which owns a 50% stake in the operator of the Pinargozu zinc mine in Turkey, said it expects to file the statements...
Brazil's Petrobras approves Chambriard as new CEO
Brazil's Petrobras approves Chambriard as new CEO
May 24, 2024
SAO PAULO, May 24 (Reuters) - Brazilian state-run oil firm Petrobras said its board of directors on Friday approved the nomination of Magda Chambriard as the company's new Chief Executive. Chambriard, who was also appointed to a seat on the board, has already taken office in the position, Petrobras said in a securities filing. ...
IAMGold Raises About US$300.2 Million With Bought Deal Financing
IAMGold Raises About US$300.2 Million With Bought Deal Financing
May 24, 2024
08:34 AM EDT, 05/24/2024 (MT Newswires) -- IAMGold ( IAG ) said Friday that it raised about US$300.2 million ($411.7 million) with its bought deal equity financing. The company offered 72 million common shares at US$4.17 apiece. IAMGOLD ( IAG ) plans to use the proceeds for the repurchase of the 9.7% interest in the Cote Gold Mine from Sumitomo...
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test
May 24, 2024
08:31 AM EDT, 05/24/2024 (MT Newswires) -- Exact Sciences ( EXAS ) said Friday it will present 10 abstracts showing its screening and diagnostic portfolio, including new data confirming the predictive and prognostic value of the Oncotype DX Breast Recurrence Score test. The company said that based on new data from two studies assessing Recurrence Score results, the test predicted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved